← Back
Data updated: Mar 10, 2026
HETERO LABS LTD VI
Oncology
HETERO LABS LTD VI is a generic drug manufacturer focused on Oncology. Key products include AZACITIDINE.
2024
Since
6
Drugs
-
Trials
47
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
OXALIPLATIN 2026-01-15
BORTEZOMIB 2026-01-06
DECITABINE 2025-12-19
BORTEZOMIB 2025-12-17
PEMETREXED DISODIUM 2025-12-15
Labeling
OXALIPLATIN 2025-10-22
Labeling
PEMETREXED DISODIUM 2025-10-09
Labeling
PEMETREXED DISODIUM 2025-08-06
Labeling
AZACITIDINE 2025-07-01
Labeling
AZACITIDINE 2025-07-01
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 100%
4 drugs
Pipeline Strength Pro
Loading...
Active (4)
Discontinued (1)
Company Info
- First Approval
- 2024-05-03
- Latest
- 2025-06-16
- Applications
- 6